Equities analysts predict that Vistagen Therapeutics Inc (NASDAQ:VTGN) will post earnings of ($0.28) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics reported earnings of ($0.32) per share in the same quarter last year, which indicates a positive year over year growth rate of 12.5%. The business is expected to announce its next quarterly earnings report on Thursday, July 5th.
On average, analysts expect that Vistagen Therapeutics will report full year earnings of ($1.08) per share for the current financial year. For the next fiscal year, analysts anticipate that the business will post earnings of ($1.09) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Vistagen Therapeutics.
Several analysts recently issued reports on VTGN shares. Oppenheimer started coverage on Vistagen Therapeutics in a report on Thursday, May 24th. They issued a “buy” rating and a $6.00 price target for the company. Zacks Investment Research upgraded Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Friday, March 30th. Finally, UBS Group started coverage on Vistagen Therapeutics in a research note on Thursday, May 24th. They set an “outperform” rating and a $6.00 target price for the company.
Institutional investors have recently made changes to their positions in the company. Sabby Management LLC acquired a new stake in shares of Vistagen Therapeutics during the fourth quarter valued at about $2,352,000. Sphera Funds Management LTD. grew its stake in shares of Vistagen Therapeutics by 17.8% during the fourth quarter. Sphera Funds Management LTD. now owns 1,247,251 shares of the company’s stock valued at $1,384,000 after acquiring an additional 188,865 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Vistagen Therapeutics by 131.6% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 104,414 shares of the company’s stock valued at $116,000 after acquiring an additional 59,338 shares in the last quarter. Institutional investors own 9.43% of the company’s stock.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.